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Introduction
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder that represents 
a leading genetic cause of  infant mortality (1, 2). SMA is caused by low levels of  the full-length survival 
motor neuron (SMN) protein, resulting from mutations or deletions in the SMN1 gene (3). SMA is primar-
ily characterized by lower motor neuron degeneration and muscle atrophy, although multisystem organ 
defects are also apparent in severe cases (2, 4). No approved treatment options currently exist for SMA.
As SMA is caused by low levels of  SMN, the majority of  therapeutic strategies currently under devel-
opment are aimed at elevating SMN levels in affected cells and tissues (5). However, limitations with 
SMN-targeted therapies have been highlighted by several animal studies, suggesting that combined thera-
pies that both increase SMN levels and target SMN-independent pathways over the life span will likely be 
required to develop a fully effective treatment (6, 7).
The ubiquitin proteasome system (UPS) represents one major cellular pathway through which SMN sta-
bility is regulated (8, 9). SMN interacts with E3 ubiquitin ligases (10) and deubiquitinating enzymes (11, 12), 
which can influence SMN levels in in vitro models. Pharmacological inhibition of  the proteasome also leads 
to reduced SMN degradation in vivo and improved neuromuscular pathology in SMA mice (13). In addi-
tion, we have previously reported that widespread disruptions in ubiquitin homeostasis are a core feature 
of  SMA pathogenesis (14–16), representing a potential SMN-independent target for therapy development.
The autosomal recessive neuromuscular disease spinal muscular atrophy (SMA) is caused by loss 
of survival motor neuron (SMN) protein. Molecular pathways that are disrupted downstream of 
SMN therefore represent potentially attractive therapeutic targets for SMA. Here, we demonstrate 
that therapeutic targeting of ubiquitin pathways disrupted as a consequence of SMN depletion, 
by increasing levels of one key ubiquitination enzyme (ubiquitin-like modifier activating enzyme 
1 [UBA1]), represents a viable approach for treating SMA. Loss of UBA1 was a conserved response 
across mouse and zebrafish models of SMA as well as in patient induced pluripotent stem cell–
derive motor neurons. Restoration of UBA1 was sufficient to rescue motor axon pathology and 
restore motor performance in SMA zebrafish. Adeno-associated virus serotype 9–UBA1 (AAV9-
UBA1) gene therapy delivered systemic increases in UBA1 protein levels that were well tolerated 
over a prolonged period in healthy control mice. Systemic restoration of UBA1 in SMA mice 
ameliorated weight loss, increased survival and motor performance, and improved neuromuscular 
and organ pathology. AAV9-UBA1 therapy was also sufficient to reverse the widespread molecular 
perturbations in ubiquitin homeostasis that occur during SMA. We conclude that UBA1 represents a 
safe and effective therapeutic target for the treatment of both neuromuscular and systemic aspects 
of SMA.
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Reduced levels of  the E1 ubiquitin-like modifier activating enzyme 1 (UBA1) were identified in the 
neuromuscular system of  SMA mice, with suppression of  Uba1 sufficient to recapitulate an SMA-like phe-
notype in zebrafish (14). Interestingly, mutations in the gene encoding UBA1 (UBA1, also known as UBE1) 
cause a very rare, non-SMN-dependent form of  SMA in human patients (17–19), indicating a fundamental 
role for UBA1 in neuromuscular stability and function. Dysregulation of  the UPS and Uba1 results in 
accumulation of  downstream UPS target proteins in SMA, including β-catenin (14). Taken together, these 
findings implicate the UPS and UBA1 as key drivers of  SMA pathogenesis, suggesting that they represent 
a potentially attractive target for therapy development.
Figure 1. UBA1 loss in patient-derived iPSC motor neurons and SMA zebrafish, with rescue of zebrafish motor pathology following Uba1 restoration. 
(A–C) Significant reduction of survival motor neuron (SMN) and ubiquitin-like modifier activating enzyme 1 (UBA1) protein in type I spinal muscular atro-
phy (SMA) patient iPSC-derived motor neurons, as quantified by Western blot (independent clones per genotype: control n = 9 and SMA n = 8; unpaired, 
2-tailed Student’s t test). (D–F) Significant reduction in Smn and Uba1 protein levels in zebrafish injected with 6 ng morpholino oligonucleotide (MO) 
targeted against Smn compared to uninjected controls, as quantified Western blot analysis (n = 3, batches of 30 fish per lane; unpaired, 2-tailed Student’s 
t test). Lanes were run on the same gel but were noncontiguous. (G) Representative micrographs of spinal motor axons from uninjected control zebraf-
ish, zebrafish injected with 4 ng Smn MO (white arrow indicates abnormal axon branching, gray arrow indicates severely truncated axons), and zebrafish 
injected with 4 ng Smn MO coinjected 200 ng/μl human UBA1 mRNA at 30 hours after fertilization (scale bar: 50 μm). (H–J) Significant improvement in the 
percentage of normal, branched, and severely truncated motor axons in zebrafish injected with 4 ng Smn MO coinjected 200 ng/μl human UBA1 mRNA  
(n = 20 per treatment group; 1-way ANOVA with Tukey’s post-hoc test). (K) Representative tracings of automated swim path analysis of uninjected control 
zebrafish, zebrafish injected with 4 ng Smn MO, and zebrafish injected with 4 ng Smn MO coinjected 200 ng/μl human UBA1 mRNA at 3 days after fertil-
ization (scale bar: 1 cm). (L) Significant improvement in the number of quadrants entered during automated swim path analysis of zebrafish injected with 
4 ng Smn MO coinjected 200 ng/μl human UBA1 mRNA (control n = 18, Smn MO n = 33, Smn MO + UBA1 n = 32; Kruskal-Wallis test with Dunn’s post-hoc 
test). *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.001.
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In the current study, we investigated whether the loss of  UBA1 observed in SMA represents a clini-
cally relevant driver of  disease pathogenesis that is amenable to safe therapeutic intervention. We show 
that suppression of  UBA1 is a conserved response to loss of  SMN in SMA, including in human SMA 
patient induced pluripotent stem cell (iPSC) derived motor neurons, with restoration of  UBA1 levels in 
a SMA zebrafish model robustly ameliorating morphological and functional motor defects. AAV9-me-
diated delivery of  UBA1 was safe and well tolerated in control mice, with restoration of  UBA1 levels in 
SMA mice leading to improvements in all neuromuscular and systemic disease parameters investigat-
ed and was also sufficient to correct molecular defects in ubiquitin homeostasis. Taken together, these 
findings represent the first demonstration to our knowledge of  a robust, systemic therapy for SMA by 
targeting ubiquitin pathways.
Results
Reduced levels of  UBA1 in SMA patient iPSC-derived motor neurons. Previous studies have reported reduced levels 
of  UBA1 protein in SMA animal models (14), but it remains unknown whether similar changes occur in 
SMA patient motor neurons. To validate UBA1 as a therapeutic target in human SMA, we measured UBA1 
protein levels in induced pluripotent stem cell–derived (iPSC-derived) motor neurons generated from type 
I SMA patients and controls (20). Quantitative Western blot analysis confirmed a significant reduction in 
SMN protein levels in SMA patient iPSCs compared with unaffected controls, accompanied by an approxi-
mately 40% reduction in UBA1 protein levels (Figure 1, A–C). Taken together with other recent iPSC stud-
ies (21), this finding confirms that UBA1 suppression represents a clinically relevant, conserved response to 
loss of  SMN protein across species, highlighting the potential to translate findings from animal models into 
human patients.
Restoration of  Uba1 rescues motor phenotypes in SMA zebrafish. It has previously been demonstrated that 
pharmacologic or genetic suppression of  Uba1 is sufficient to recapitulate the SMA motor phenotype 
generated by Smn knockdown in zebrafish (14). We therefore used the zebrafish SMA model system as 
an initial in vivo platform to investigate whether experimental restoration of  Uba1 has the potential to 
ameliorate the SMA phenotype. Western blot analysis revealed an approximately 70% reduction in Uba1 
protein levels in zebrafish following Smn knockdown compared with controls (Figure 1, D–F). Coinjec-
tion of  full-length human UBA1 mRNA ameliorated motor axon morphological defects in SMA zebrafish, 
significantly reducing the incidence of  abnormally branched or truncated axons (Figure 1, G–J). In addi-
tion, coinjection of  UBA1 mRNA improved the functional motor capacity of  SMA zebrafish (Figure 1, 
K and L). Thus, experimental restoration of  Uba1 levels robustly rescued functional and morphological 
motor defects in a vertebrate model of  SMA.
AAV9-UBA1 delivers a safe, systemic increase in UBA1 levels. Due to the promising phenotypic improve-
ments observed in our zebrafish model, we next wanted to establish whether a similar phenotypic rescue 
could be generated in SMA mice using a gene therapy approach. Due to the large size of  the UBA1 gene 
and limited packaging capacity of  self-complementary adeno-associated virus (AAV) (22), vector sub-
cloning was constrained to conventional AAV9. Following generation of  AAV9 containing a full-length 
human UBA1 open reading frame (AAV9-UBA1; see Methods; Supplemental Figure 1; supplemental 
material available online with this article; doi:10.1172/jci.insight.87908DS1), we wanted to establish 
whether we could systemically increase UBA1 levels in vivo and determine whether increased levels of  
UBA1 are safe and well tolerated.
Initial biodistribution studies using Evans blue dye illustrated that intravenous injection via the 
facial vein led to superior systemic distribution compared with intraperitoneal injection (Supplemental 
Figure 2); intravenous injection was therefore utilized for subsequent gene therapy delivery. Intravenous 
injection of  AAV9-UBA1 at P1 into control healthy mice led to significant increases in UBA1 protein 
levels in the spinal cord, muscle, heart, liver, lung, and kidney by P7 (Figure 2, A and B). No change in 
UBA1 protein levels was observed in the brain by P7. This finding was consistent with temporal expres-
sion profiles obtained from a parallel biodistribution analysis of  AAV9-mediated expression in mice, 
showing that CNS expression was slower to appear than that in other tissues and organs (Supplemen-
tal Figure 3, A–E). qRT-PCR analysis using primers designed to specifically detect human or mouse 
UBA1 revealed that the UBA1 increase seen in tissue from AAV9-UBA1–injected mice was exclusively 
attributable to virally delivered human UBA1 cDNA expression, as mouse Uba1 mRNA levels remained 
unchanged (Figure 2, C and D).
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Figure 2. AAV9-UBA1 gene therapy delivers safe systemic increases in UBA1 expression. (A and B) Adeno-associated virus serotype 9–ubiquitin-like 
modifier activating enzyme 1 (AAV9-UBA1) delivered at P1 significantly increased UBA1 protein levels in spinal cord, gastrocnemius muscle, heart, liver, 
lung, and kidney in P7 control mice (n = 3 mice per group; unpaired 2-tailed Student’s t test). Lanes were run on the same gel but were noncontiguous. 
(C) PCR products following mouse, human, and UBA1 viral cDNA amplification using primers detecting both mouse Uba1 and human UBA1 cDNA (top 
row), unique to mouse Uba1 cDNA (middle row), and unique to human UBA1 cDNA (bottom row). (D) Significant increase in AAV-expressed human UBA1 
mRNA, but not endogenous mouse Uba1 mRNA, in the hearts of P7 AAV9-UBA1–treated mice (n = 3 mice per group; unpaired, 2-tailed Student’s t test). 
(E) Representative Nissl-stained spinal cords (ventral horn) from uninjected control and AAV9-UBA1–treated control mice at P9 (scale bar: 250 μm). (F) 
No significant change in the number of motor neurons in the spinal cords of AAV9-UBA1–treated control P9 mice (n = 4 mice per group; unpaired, 2-tailed 
Student’s t test). (G) Representative confocal micrographs of neuromuscular junctions (NMJs) in the external oblique from uninjected control and AAV9-
UBA1–treated control mice at P9 (axonal inputs in green; postsynaptic endplates in red; scale bar: 25 μm). (H) No significant change in axonal inputs at 
the NMJ in the external oblique muscle of AAV9-UBA1–treated control mice at P9 (n = 4 mice per group; unpaired, 2-tailed Student’s t test). (I) Uninjected 
control and AAV9-UBA1–treated control mice at P180 (scale bar: 2 cm). (J–L) No change in AAV9-UBA1–treated controls from P1 to P180 with respect to (J) 
weight (at P180 n = 4 mice per group), (K) survival (Kaplan-Meier survival analysis), or (L) righting reflex test performance (from P1 to P12–P14; unpaired, 
2-tailed Student’s t test at each time point). ns (not significant) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001. As part of a different com-
parative analysis, uninjected littermate control data concerning motor neuron cell body counts (F) and NMJ axonal input (H) is also shown in Figure 5, B 
and D, respectively. Weight, survival and righting times (J–L) for uninjected controls are also shown in Figure 4, A–C.
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Neuropathological analyses of  AAV9-UBA1–treated control mice at P9 showed no detectable changes 
in spinal motor neuron number or morphology (Figure 2, E and F), neuromuscular junction (NMJ) integ-
rity (Figure 2, G and H, and Supplemental Figure 4, A and C), or muscle fiber diameter (Supplemental 
Figure 4, B and D). In a longer-term safety study, the appearance (Figure 2I), weight (Figure 2J), survival 
(Figure 2K), and motor performance (Figure 2L) of  AAV9-UBA1 mice remained indistinguishable from 
uninjected control mice throughout (endpoint of  P180). To investigate whether any underlying, systemic 
physiological alterations were induced following AAV9-UBA1 injection, hematology analysis and serum 
biochemistry screens were conducted. No significant alterations in any of  the 19 hematology parameters 
(Supplemental Table 1) or the 11 serum biochemistry parameters (Supplemental Table 2) were noted in 
AAV9-UBA1–treated mice. Together, these data illustrate that a robust systemic increase in UBA1 proteins 
is achievable using AAV9 gene therapy, with the high resulting levels of  UBA1 being well tolerated, with 
no obvious adverse effects.
Figure 3. Systemic reductions in Uba1 protein in SMA mice can be restored with AAV9-UBA1 gene therapy. (A) Quantification of ubiquitin-like modifier 
activating enzyme 1 (Uba1) levels in the spinal cord, gastrocnemius muscle, heart, liver, lung, kidney, and brain of spinal muscular atrophy (SMA) mice at 
P1, P3, P7, and P11 by western blot analysis, expressed as a percentage of control values (n = 3 mice for each genotype at each time point). (B and C) Intra-
venous adeno-associated virus serotype 9–UBA1 (AAV9-UBA1) gene therapy at P1 leads to a significant increase in UBA1 protein levels in the spinal cord, 
gastrocnemius muscle, heart, liver, lung, and kidney (but not whole brain) in P7 SMA mice, as quantified by Western blot (n = 3 mice per treatment group, 
except for spinal cord, for which n = 5; unpaired 2-tailed Student’s t test). Lanes were run on the same gel but were noncontiguous. (D) Representative 
confocal micrographs showing increased UBA1 levels (green) in the heart, liver, and motor neurons in the spinal cord ventral horn of P7 AAV9-UBA1–treated 
mice compared to uninjected SMA mice. Hearts and livers were colabeled with DAPI and the spinal cord fluorescent Nissl stain (blue) (scale bar: 50 μm). ns 
(not significant) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005.
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Systemic restoration of  UBA1 protein levels in SMA mice using AAV9-UBA1. We have previously character-
ized UBA1 perturbations in the neuromuscular system of  SMA mouse models (14). However, considering 
the growing body of  evidence suggesting involvement of  other organ systems in SMA pathology (4), we 
wanted to establish what other organs and tissues also showed UBA1 depletion in “Taiwanese” SMA 
mice in order to determine critical target sites for delivering AAV9-UBA1. Western blot analysis revealed 
that all nonneuronal organs examined had perturbations in UBA1 levels, with the heart being particularly 
affected, followed by the liver, skeletal muscle, kidney, lung, and spinal cord (Figure 3A). Reduced UBA1 
levels in organs correlated with disease progression, with changes occurring during presymptomatic/early 
symptomatic stages of  disease (Figure 3A) suggesting that early, systemic delivery of  AAV9-UBA1 would 
be required in SMA mice.
Similar to previous experiments in control mice, intravenous injection of AAV9-UBA1 into “Taiwanese” 
SMA mice at P1 led to a significant increase in UBA1 protein levels in the spinal cord, muscle, heart, liver, lung, 
and kidney of control mice by P7 (Figure 3, B and C). Immunohistochemical analysis confirmed increased 
UBA1 protein levels in the heart, liver, and spinal cord motor neurons of SMA mice treated with AAV9-UBA1, 
with a predominantly nuclear localization consistent with the presence of a nuclear localization signal in full-
length human UBA1 (23) (Figure 3D).
AAV9-UBA1 improves weight, survival, and motor performance of  SMA mice. To establish whether delivery of  
AAV9-UBA1 could improve the phenotype of  SMA mice, the weight, survival, and motor performance of  
AAV9-UBA1–treated SMA mice were monitored following intravenous injection at P1. At late-symptom-
atic ages, the weight of  AAV9-UBA1 SMA mice was improved compared with uninjected SMA mice. For 
Figure 4. Improved body weight, survival, and motor performance of SMA mice treated with AAV9-UBA1. (A) Average weights of adeno-associated 
virus serotype 9–ubiquitin-like modifier activating enzyme 1–treated (AAV9-UBA1–treated) control mice (n = 28 at P3), uninjected spinal muscular atrophy 
(SMA) mice (n = 25 at P3), and AAV9-UBA1–treated SMA mice (n = 19 at P3). (B) Survival analysis of AAV9-UBA1–treated control mice (n = 19), uninjected 
SMA mice (n = 25), and AAV9-UBA1–treated SMA mice (n = 11) (Kaplan-Meier survival analysis). (C) Average righting reflex times of AAV9-UBA1–treated 
control mice (n = 28 at P3), uninjected SMA mice (n = 25 at P3), and AAV9-UBA1–treated SMA mice (n = 19 at P3). (D) Representative photographs of a 
AAV9-UBA1–treated control mouse, uninjected SMA mouse, and a AAV9-UBA1–treated SMA mouse at P9 (scale bar: 2 cm). ****P ≤ 0.001. As part of a 
different comparative analysis, weight, survival and righting times (A–C) for uninjected controls are also shown in Figure 2, J–L.
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example, at P8 AAV9-UBA1–treated mice weighed 2.5 ± 0.1 g (n = 15) compared with uninjected SMA 
mice at 1.9 ± 0.06 g (n = 15) (P ≤ 0.001) (Figure 4A). Survival of  SMA mice was also improved following 
AAV9-UBA1 delivery, with treated mice displaying a median survival age of  P12 (n = 11) compared with 
P9 for uninjected SMA mice (n = 25) (P ≤ 0.001) (Figure 4B). Righting reflex times (a robust measure of  
neuromuscular function in neonatal mice) were strikingly improved to near control levels from P4 to P7 in 
SMA mice treated with AAV9-UBA1, with those mice living to P17 still able to right themselves (Figure 4C). 
At late-symptomatic stages of  disease, AAV9-UBA1–treated SMA mice had a healthier overall appearance 
compared with untreated SMA animals (Figure 4D).
AAV9-UBA1 rescues neuromuscular and systemic pathology in SMA mice. Given that AAV9-UBA1 treatment 
had a beneficial effect on the gross phenotype of SMA mice, we next analyzed the effect of increasing UBA1 
levels on late-stage (P9) neuromuscular and organ pathology. In the neuromuscular system, AAV9-UBA1–
treated SMA mice displayed a significant improvement in spinal motor neuron survival (Figure 5, A and B), 
a reversal of NMJ pathology (Figure 5, C and D, and Supplemental Figure 4, A and C), and restored muscle 
fiber diameters (Figure 5, E and F, and Supplemental Figure 4, B and D). The gross appearance of the heart 
was noticeably improved in AAV9-UBA1–treated SMA mice (Figure 6A), as reflected in an increased heart 
length (Figure 6B), heart weight (Figure 6C), and heart-weight-to-body-weight ratio (Figure 6D). H&E anal-
ysis of liver pathology in SMA mice revealed an increased number of nucleated cells and megakaryocytes 
(Figure 6E). Ly76/DAPI immunohistochemistry showed that SMA mouse livers have an accumulation of  
erythrocytes and nucleated erythrocyte precursors (Figure 6, E–G). AAV9-UBA1 treatment ameliorated mega-
karyocyte numbers (Figure 6E), Ly76+ erythrocyte accumulation (Figure 6, E and F), and nucleated Ly76+ 
erythrocyte precursor cell numbers (Figure 6, E and G), indicating a rescue of liver cellular pathology.
AAV9-UBA1 treatment corrects expression of  downstream UPS/UBA1 targets and increases SMN levels in SMA 
mice. Next, we wanted to establish whether AAV9-UBA1 therapy was generating phenotypic improvements 
in SMA by correcting molecular perturbations known to occur downstream of  UBA1 disruption in SMA. 
As the heart had the highest fold changes in UBA1 protein levels following gene therapy delivery (Figure 
Figure 5. Rescue of neuromuscular and systemic pathology in SMA mice treated with AAV9-UBA1. (A) Nissl-stained spinal cords (ventral horn) from 
uninjected control, uninjected spinal muscular atrophy (SMA), and adeno-associated virus serotype 9–ubiquitin-like modifier activating enzyme 1–treated 
(AAV9-UBA1–treated) SMA mice at P9 (scale bar: 250 μm). (B) Significant rescue of motor neurons in AAV9-UBA1–treated SMA mice at P9 (n = 4 mice per 
group). (C) Confocal micrographs of neuromuscular junctions (NMJs) in the external oblique from uninjected control, uninjected SMA, and AAV9-UBA1–
treated SMA mice at P9 (axonal inputs in green; postsynaptic endplates in red; scale bar: 25 μm). (D) Significant improvement in NMJ pathology in the 
external oblique muscle of AAV9-UBA1–treated SMA mice at P9 (n = 4 mice per group). (E) Bright-field micrographs of individual teased muscle fibers from 
the external oblique of uninjected control, uninjected SMA, and AAV9-UBA1–treated SMA mice at P9 (scale bar: 100 μm). (F) Significant rescue of muscle 
fiber diameters in AAV9-UBA1–treated SMA mice at P9 (n = 4 mice per group). One-way ANOVA with Tukey’s post-hoc test for all analyses. *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001. As part of a different comparative analysis, uninjected littermate control data motor neuron cell body counts (B) and 
NMJ axonal input (D) is also shown in Figure 2, F and H, respectively.
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2, A and B, and Figure 3, B and C), we chose to conduct these investigations in heart tissue from control 
and SMA mice. Western blot analyses of  a panel of  proteins known to be perturbed in SMA mice as a con-
sequence of  reduced Uba1 levels (14) revealed a correction in levels of  β-catenin as well as restoration of  
monoubiquitin and polyubiquitin in SMA mice treated with AAV9-UBA1 (Figure 7, A–D).
Given that SMN degradation is predominately regulated by the UPS (9), we next wanted to establish 
whether AAV9-UBA1 treatment resulted in altered levels of SMN. Western blot analysis revealed that higher 
levels of UBA1 protein in both control and SMA mice (Figure 7F) resulted in a significant increase in levels 
of SMN protein (Figure 7, E and G). No change in the levels of either UBA1 or SMN protein was detected 
in control or SMA mice that received an intravenous injection of AAV9-GFP (Supplemental Figure 5, A–D), 
indicating that the SMN increase in AAV9-UBA1–treated tissue was occurring as a direct result of UBA1 over-
expression, rather than as a secondary consequence of AAV injection. qRT-PCR quantification of Δ7-SMN 
and full-length SMN (FL-SMN) mRNA expression in AAV9-UBA1–treated SMA mice revealed that, while 
Δ7-SMN expression was not significantly changed, FL-SMN mRNA levels were increased compared with unin-
Figure 6. Rescue of heart and liver pathology in SMA mice treated with AAV9-UBA1. (A) Uninjected control, uninjected spinal muscular atrophy 
(SMA), and adeno-associated virus serotype 9–ubiquitin-like modifier activating enzyme 1–treated (AAV9-UBA1–treated) SMA mouse hearts and 
livers at P9 (scale bar: 0.5 cm). (B–D) Significant improvement in heart pathology in P9 AAV9-UBA1–treated SMA mice for the parameters of (B) heart 
length (n = 4 mice per group), (C) heart weight (control n = 5, SMA n = 11, SMA + AAV9-UBA1 n = 4), and (D) heart-weight-to-body-weight ratio (control 
n = 5, SMA n = 7, SMA + AAV9-UBA1 n = 4). (E) Histological analysis of uninjected control, uninjected SMA, and AAV9-UBA1 SMA P9 livers. Top row 
shows H&E-stained micrographs (white arrows indicate hematopoietic islands; black arrows indicate megakaryocytes; scale bar: 25 μm). Middle row 
shows micrographs of Ly76 immunohistochemistry (scale bar: 25 μm). Bottom row shows micrographs (scale bar: 25 μm) along their magnified insets 
(scale bar: 12.5 μm) costained with the Ly76 marker (green) and DAPI (blue). (F and G) Significant improvements in (F) liver Ly76+ erythrocyte area and 
(G) liver erythrocyte precursor cell area of AAV9-UBA1–treated SMA mice at P9 (n = 4 mice per group). One-way ANOVA with Tukey’s post-hoc test for 
all analyses. **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001.
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jected controls (Figure 7, H and I). Thus, increased levels of UBA1 resulting from AAV9-UBA1 delivery were 
likely influencing SMA pathology via correcting defects in known UPS/UBA1 targets (e.g., β-catenin and 
ubiquitin homeostasis) as well as through modestly increasing levels of full-length SMN protein.
Discussion
Recent studies have identified widespread dysregulation of  ubiquitin homeostasis as a conserved molec-
ular hallmark of  SMA. Here, we demonstrate that ubiquitin pathway defects represent a key driver of  
both neuromuscular and systemic pathology in SMA, with targeting of  UBA1 representing a safe and 
effective approach for developing novel and effective SMN-independent therapies. Our finding that UBA1 
suppression occurred in iPSC-derived human SMA motor neurons, with a similar magnitude of  response 
to that previously reported in animal models (14), confirms that UBA1 represents a valid and attractive 
therapeutic target for clinical translation. The subsequent demonstration that restoration of  Uba1 in zebraf-
ish generated a robust rescue of  functional and morphological neuromuscular defects therefore represents 
Figure 7. AAV9-UBA1 gene therapy corrects UPS perturbations and increases FL-SMN mRNA and protein levels. (A–D) Western blot analysis of 
β-catenin, polyubiquitin, and monoubiquitin protein levels in uninjected spinal muscular atrophy (SMA) and adeno-associated virus serotype 9–
ubiquitin-like modifier activating enzyme 1 (AAV9-UBA1) SMA mouse hearts at P7 (n = 3 mice per treatment group; unpaired 2-tailed Student’s t 
test). Lanes were run on the same gel but were noncontiguous. (E–G) Western blot analysis of UBA1 and survival motor neuron (SMN) protein levels 
in uninjected control, uninjected SMA, AAV9-UBA1–treated control, and AAV9-UBA1–treated SMA P7 hearts (n = 3 mice per group; 1-way ANOVA with 
Tukey’s post-hoc test). (H) PCR products following mouse, human, and UBA1 viral cDNA amplification using primers that detect full-length SMN  
(FL-SMN) (top row) or Δ7-SMN (bottom row). (I) Significant increase in FL-SMN, but not Δ7-SMN, mRNA expression in the hearts of AAV9-UBA1–
treated mice at P7, as detected by qRT-PCR quantification using the primers shown in H (n = 3 mice per treatment group; unpaired 2-tailed Student’s 
t test). ns (not significant) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001.
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an important proof-of-concept demonstration that targeting UBA1 can be sufficient to ameliorate disease 
pathogenesis in SMA. Taken together with our detailed AAV9-UBA1 safety and efficacy studies in mice, 
this provides support for the notion that UPS perturbations in SMA are a clinically relevant molecular 
defect representing a viable therapeutic target in human patients.
The demonstration that elevated levels of  UBA1 resulting from treatment with AAV9-UBA1 were safe 
and well tolerated in vivo (both in healthy and SMA mice) is particularly encouraging. This may be par-
ticularly pertinent as gene mutations or alterations in UBA1 expression have been associated with cell 
proliferation (24) and cancer (25, 26). Reassuringly, no obvious signs of  gross tumor formation were noted 
over a 6-month period in control mice treated with AAV9-UBA1, consistent with previous work showing 
that syngeneic transplantation of  UBA1-overexpressing melanoma cells did not significantly affect tumor 
formation in mice (25). This increased our confidence in our ability to selectively target and correct defec-
tive aspects of  the UPS in SMA (in this case, not only rectifying UBA1 suppression, but also consequently 
correcting monoubiquitin and polyubiquitin levels as well as downstream substrate targets such as β-caten-
in) without destabilizing the entire system or generating unintended phenotypes. The fact that high levels of  
UBA1 are well tolerated is perhaps not too surprising, considering that UBA1 is in the top 2% of  the most 
abundant cellular proteins (27), suggesting that cells already have the capacity to handle high levels of  this 
important protein.
Our finding that AAV9-UBA1 gene therapy was able to rescue neuromuscular pathology in SMA mice, 
with associated improvements in body weight, survival, and motor performance, confirms that targeting of  
UBA1 represents a valid approach to therapy development for SMA (alone or in combination with other 
SMN-targeted therapies). Systemic pathology in the heart and liver were also ameliorated following AAV9-
UBA1 delivery. The liver phenotype described here, whereby greater numbers of  hematopoietic elements 
such as erythrocyte precursor cells and megakaryocytes are seen due to SMN depletion, resembles that of  
liver conditional SMN knockout mice (28). The liver is the main hematopoietic organ during embryonic 
development, but this function is rapidly lost in the early postnatal period as bone marrow takes over (29). 
As bone development in SMA is impaired (30), it may therefore be unable to support hematopoiesis, lead-
ing to persistent erythropoiesis in the liver. As this pathology is ameliorated by UBA1 overexpression, it 
seems likely that such changes in hematopoiesis are due to aberrant rather than delayed liver development.
The robust neuromuscular and systemic phenotypic improvements we report are perhaps even more 
striking when viewed in light of  the fact that we were restricted to the use of  “standard” (i.e., not self- 
complimentary) AAV9 vectors, resulting in a slower onset of  UBA1 expression than we might have other-
wise desired. This point is particularly important to note in light of  several recent studies demonstrating that 
SMN-dependent therapies have a very narrow time window of effectiveness (essentially the first few days of  
life) in SMA mice (31–33). Moreover, the increased survival we obtained using AAV9-UBA1 in the severe 
“Taiwanese” SMA mouse model (with a life expectancy of  ~9 days in our hands at present) is very similar 
in magnitude to the increase in survival previously reported in studies restoring SMN with AAV9 in compa-
rable severe SMA mouse models (34) (in contrast to studies using the milder Δ7 SMA mouse model). Thus, 
next-generation therapeutic strategies capable of  delivering a more rapid targeting of  UBA1 levels and/or 
activity may have an even better potential to modify core disease parameters in SMA. In addition, it is tempt-
ing to speculate that combined delivery of  UBA1-targeted therapies alongside SMN-targeted therapies may 
offer the potential to generate a more robust, systemic improvement in disease symptoms than either UBA1- 
or SMN-directed treatments alone. Furthermore, the UBA1-targeted therapies we report here may represent 
novel treatment options for patients with X-linked SMA due to mutations in the UBA1 gene (17–19).
Molecular analysis of  AAV9-UBA1–treated SMA mouse hearts showed that the virally delivered 
human UBA1 gene was functional in mice in vivo, with increased UBA1 levels sufficient to correct down-
stream UPS perturbations, reducing β-catenin and increasing monoubiquitin and polyubiquitin levels previ-
ously identified in SMA mice (14). This correction of  downstream UPS perturbations is likely to contribute 
directly to the improved motor performance of  SMA mice following UBA1 gene therapy, as inhibition of  
the UBA1 downstream target β-catenin has previously been shown to improve neuromuscular phenotypes 
in the same SMA mouse model (14). In addition, examination of  SMN levels in the treated mice revealed 
that increasing UBA1 levels resulted in modestly increased expression of  FL-SMN mRNA and SMN pro-
tein in vivo. Although the magnitude of  increase in SMN expression is unlikely to explain all the pheno-
typic improvements observed in SMA mice following UBA1 gene therapy, it is likely to be contributing, 
at least in part, to the amelioration of  disease symptoms. While it is known that the UPS regulates SMN 
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degradation (8, 9), our findings suggest that further work is now required to fully determine the specific role 
of  UBA1 in this process.
Our current findings, taken together with previous studies showing that loss-of-function mutations in 
UBA1 cause X-linked SMA (17–19) and that Uba1 loss-of-function Drosophila (35–37) and C. elegans (38) 
mutants display motor impairments, provide a direct demonstration that UBA1 is required for maintenance 
of  a healthy neuromuscular system and for normal neuronal function. Similarly, emerging evidence sug-
gests that UBA1 dysregulation may be implicated in other neurodegenerative diseases (39) and may also 
play a role in neuroprotection (for example, UBA1 levels are increased in neurons from Wlds mice protected 
from Wallerian degeneration; refs. 40, 41). Thus, the development of  UBA1-targeted therapies for SMA 
reported here may have potential relevance to a broad range of  other neurodegenerative conditions.
Methods
Zebrafish Smn knockdown and UBA1 restoration. Smn morpholino oligonucleotides (MO) were designed 
against the 5′ start sequence of  the Smn gene (Gene Tools LLC), 5′-CGACATCTTCTGCACCATTG-
GC-3′ (42). Full-length human UBA1 (NM_003334.3) was ligated into a PCS2+MT vector using BamH1 
restriction sites. The UBA1 construct was used to generate UBA1 mRNA for overexpression experiments. 
Single-cell stage Tg(mnx1:GFP ml2) embryos (43) were injected with 4 ng Smn MO in aqueous solution con-
taining 0.05% phenol red or 4 ng Smn MO coinjected 200 ng/μl human UBA1 mRNA in aqueous solution. 
Uninjected zebrafish were used as controls. Zebrafish embryos and litters of  mice were randomly assigned 
to treatment groups. Unfertilized or severely deformed embryos were excluded from analysis. Sample size 
estimates were based on previous analyses using these models (14).
Zebrafish motor axon phenotype analysis. For immunostaining, uninjected Smn MO and Smn MO + UBA1 
Tg(mnx1:GFP ml2) embryos were dechorinated at 30 hours after fertilization and fixed in 4% PFA overnight 
before being dehydrated in 100% methanol. Embryos were rehydrated and washed in PBS before being 
transferred into 100% acetone for 10 minutes at –20°C for permeabilization. Embryos were washed in PBST 
(PBS, 1% DMSO, 1% BSA and 0.5% Triton-X 100) before being blocked in PBST plus 2% sheep serum, fol-
lowed by overnight incubation of  chicken anti-GFP primary antibody (1:1,000; Abcam; ab13970). Embryos 
were washed in PBST and then incubated in Alexa Fluor 488 secondary antibody (1:500; Jackson Immu-
noResearch; 703-545-155). Embryos were mounted in 80% glycerol and imaged at ×20 objective using a 
Zeiss LSMZ10 confocal microscope. The percentage of  motor neurons with normal axons, branched axons, 
and severely abnormally truncated axons was then analyzed as previously described (14) (n = 20 per group, 
12 axons per embryo [6 segments] analyzed behind the yolk). Motor axon analysis was performed by inves-
tigators blinded to the treatment group.
Zebrafish behavioral testing. Uninjected (n = 18), Smn MO (n = 33), and Smn MO + UBA1 (n = 32) Tg(mnx-
1:GFP ml2) embryos were left to develop until 3 days after fertilization before behavioral analysis. Three days 
after fertilization, embryos were touched with a glass capillary on the tail end. Their swim path was recorded 
over 15 seconds and analyzed using a Noldus behavior analysis setup and EthoVision software (version 7). 
The swim arena was divided into quadrants, and the data were analyzed based on how many quadrants the 
embryos entered. Recordings of  each embryo were performed 3 times, and the mean was taken.
Preparation of  zebrafish for Western blot analysis. Wild-type AB strain 1-cell stage embryos were injected 
with 6 ng of  smn MO and left to develop until 48 hours after fertilization. Embryos were dechorinated and 
deyolked in 1 ml of  deyolking buffer (1/2 Ginzburg Fish Ringer without calcium: 55 mM NaCl, 1.8 mM 
KCl, 1.25 mM NaHCO3). Embryos were pooled into batches of  30 fish, with 3 replicate batches per experi-
mental group. Zebrafish were pelleted at 300 g for 30 seconds, and the supernatant was discarded. Zebrafish 
were washed twice with wash buffer (110 mM NaCl, 3.5 mM KCl, 2.7 mM CaCl2, 10 mM Tris, pH 8.5) and 
cells were pelleted at 300 g for 30 seconds. The supernatant was removed, and cells were stored at –80°C.
SMA patient and control iPSC-derived motor neurons. iPSC-derived motor neurons were generated by 
reprogramming Coriell Biorepository patient fibroblasts as previously described (20) (n = 8 independent 
clones of  control iPSC motor neurons were generated from fibroblast line GM03814 and n = 9 independent 
SMA clones generated from fibroblast lines GM03813 or GM00232). Western blot analysis was performed 
on cells that were harvested at 14 days after differentiation.
AAV production. AAV9-UBA1 and AAV-GFP were produced as previously described (44). Briefly, 
HEK293T cells cultured in 15-cm dishes were transfected with 26 μg Helper plasmid (pHelper) (Strata-
gene), 13 μg packaging plasmid (pAAV2/9) (provided by J. Wilson, University of  Pennsylvania, Phila-
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delphia, Pennsylvania, USA), and 13 μg pAAV-CMV-UBAI plasmid using polyethylenimine (PEI, linear, 
MW 25,000) (Polysciences Inc., 23966) transfection method. Five days after transfection, the supernatant 
was collected and treated with Benzonase nuclease (Sigma-Aldrich, E1014-25KU) for 2 hours at 37°C. 
The supernatant was then centrifuged (3,850 g for 5 minutes) in order to be clarified from cell debris before 
being filtered using a 0.22-μM vacuum filter. It was then concentrated by approximately 75 times using 
Amicon Ultra-15 Centrifugal 100K filter units. AAV purification by iodixanol density gradient and collec-
tion of  the 40% layer containing the virus was performed following concentration. Purified, concentrated, 
and desalted AAV vector was then titered using qPCR. The vector map for AAV-UBA1 containing the full-
length human UBA1 open reading frame (NM_003334.3) is shown in Supplemental Figure 1.
Mouse model of  SMA. The “Taiwanese” mouse model of  severe SMA (Smn-/-; SMN2tg/0) on a congenic 
FVB background was used throughout (45), utilizing a previously described breeding strategy (46). Age-
matched, phenotypically normal littermate mice (Smn+/-; SMN2tg/0) were used as controls, and litters were 
retroactively genotyped using standard PCR protocols (46). Mice were originally obtained from Jackson 
Laboratories and were maintained in animal care facilities at the University of  Edinburgh under standard 
specific pathogen–free conditions. CD1 mice were used as wild-type animals for AAV9-GFP biodistribu-
tion analyses.
AAV9 gene therapy delivery. For all gene therapy analysis, data from uninjected littermate controls, AAV9-
UBA1 littermate controls, uninjected SMA mice, and AAV9-UBA1 injected mice was obtained from the 
same set of  experiments. For subsequent analysis, we present different comparisons between these 4 exper-
imental groups, hence the repeated presentation of  data for the uninjected control experimental group in 
some figures.
An initial biodistribution study assessed the spread of  Evans blue dye (1% w/v; Sigma-Aldrich) follow-
ing delivery of  a 10-μl injection volume to the intraperitoneal cavity or intravenously via the facial vein. As 
intravenous injections were found to be superior at achieving systemic distribution, all subsequent delivery 
of  gene therapy was given via injection into the facial vein in TTG or CD1 wild-type mice, conducted under 
chilled anesthesia using a 33-gauge needle and Hamilton syringe (Supplemental Figure 2). AAV9-UBA1 was 
administered at the day of  birth (P1) at a concentration of  2.4 × 1011 vg/mouse and AAV9-GFP was admin-
istered at a concentration of  1.4 × 1011 vg/mouse at a 10-μl injection volume. Visualization of  the facial vein 
for intravenous injection was aided by using a Wee Sight Transilluminator LED light (Philips) (Supplemen-
tal Figure 2). Successful intravenous injection was noted by blanching of  the vein during injection. Bleeding 
at the injection site was minimized by applying pressure with a tissue. Pups were held in the hand until their 
temperature and movement returned to normal; then they were placed into a cage with a CD1 foster mother. 
Uninjected mice were used as controls. Whole litters of  mixed male/female pups were used. Litters of  mice 
were randomly assigned to treatment groups. Sample size estimates were based on previous analyses using 
these models (14). Whole litters of  mice were excluded from the study if  there was evidence of  clear mater-
nal neglect (e.g., cannibalization or lack of  feeding).
Weights, survival, and righting test. Mice assigned to each of  the treatment groups were weighed on a 
daily basis. For long-term analysis of  uninjected and AAV9-UBA1–treated controls, mice were weighed on 
a monthly basis. Kaplan-Meier survival analyses were performed on uninjected or AAV9-UBA1–treated 
mice as previously described (47). For SMA mice, a predetermined endpoint of  survival was based on an 
evaluation of  their established and robust clinical phenotype (14) and/or weight loss of  20% from the peak 
body weight of  that animal, persisting for 72 hours. To assess motor performance of  uninjected or AAV9-
UBA1–treated mice, a righting reflex was performed daily as previously described (48). For each daily 
session, the righting reflex test was performed 3 times and the mean was taken.
Neuromuscular analysis. Analysis of  neuromuscular pathology was performed on uninjected control, 
uninjected SMA, control + AAV9-UBA1, and SMA + AAV9-UBA1 P9 mice (n = 4 for each group). Spinal 
motor neuron cell body counts were performed as previously described (15). NMJ pathology was per-
formed on whole-mount external oblique and transversus abdominis muscles as previously described (49). 
Example images were taken using a Nikon A1R confocal system combined with a Ti:E inverted micro-
scope (×60 objective). Muscle fiber diameter measurements were taken from phase-contrast micrographs of  
external oblique and transversus abdominis muscle preparations using ImageJ software (NIH) as previously 
described (50). Bright-field images of  spinal motor neurons and muscle fiber diameters were taken using a 
Leica DMIRB microscope equipped with a Retiga 2000R camera and QCapturePro-6 software (×20 objec-
tive). Neuromuscular analysis was performed by investigators blinded to the treatment group.
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Heart and liver analysis. Freshly dissected hearts from P9 uninjected control (n = 5), uninjected SMA 
(n = 11) and SMA + AAV9-UBA1 (n = 4) mice were immediately weighed using a microbalance. The 
heart-weight-to-body-weight ratio was calculated by dividing the weight of  the freshly dissected hearts by 
the whole-body weight for each animal. Heart length was determined by cyrosectioning the whole length 
of  heart from apex to base. Each 12-μm heart section was collected on to slides and processed by H&E 
staining, and the sum of  total section number per heart was multiplied by 12 to give the length in μm. Anal-
ysis of  liver pathology in P9 uninjected control, uninjected SMA, and SMA + AAV9-UBA1 mice (n = 4 
mice for each group) was performed using H&E staining, Ly76, and DAPI immunohistochemistry (details 
below). For microstructural analysis, livers fixed in 4% paraformaldehyde were transferred to 70% ethanol 
and wax embedded before being cut at 3 μm on a microtome and stained with H&E using a standard pro-
tocol. Sections were visualized using a Nikon eclipse e400 microscope (×10 objective), and images were 
captured using a QICAM Fast 1394 camera and Improvision Velocity 4 image capture software. Ly76 den-
sity quantification was performed using ImageJ (NIH). Cells that were positive for Ly76 and DAPI were 
classified as erythrocyte precursor cells.
Hematology and serum biochemistry analysis. Under terminal anesthesia, blood was collected via cardiac 
puncture from uninjected P30 control littermate mice or P30 control mice that had received an AAV9-
UBA1 injection at P1 (n = 3 per group). Blood was collected into heparin- and EDTA-coated tubes, kept 
on ice, and immediately taken for further processing. Hematology analysis was performed using a ABX 
Pentra 60 hematology analyser (Horiba Ltd.), with the differential white blood cell counts and differential 
done manually (100-cell count) on blood smears stained with modified Wright’s stain. Analysis of  serum 
biochemistry was performed using an IL650 biochemistry analyser (Diamond Diagnostics) with assay kits 
from Randox Ltd. (Crumlin).
Quantitative fluorescent Western blot analysis. Tissue for Western blot analysis was quickly dissected, 
placed on dry ice, and stored at –80°C. Protein was extracted in RIPA buffer (ThermoScientific) with 1% 
protease inhibitor cocktail (Sigma-Aldrich), and the protein concentration was then determined by BCA 
assay (ThermoScientific). SDS-PAGE was performed using precast NuPage 4%–12% BisTris gradient gels 
(Life Technologies) and transferred to PVDF membranes by the iBlot 7 minute semi-dry blotting system 
(Life Technologies). Following Ponceau S stain and blocking, membranes were incubated overnight at 4°C 
using the following primary antibodies: mouse anti-ubiquitin (clone Uba-1) (1:1,000, Merck Millipore, 
MAB1510), mouse anti-SMN (1:1,000, BD Biosciences, 610646), mouse anti–β catenin (1:1,000, BD Bio-
sciences, 610153), rabbit-anti UBE1a,b (1:1,000, ThermoFischer, PA5-17274), rabbit anti-E1 ubiquitin acti-
vating enzyme (1:1,000, Abcam, ab34711), rabbit anti-GFP (1:2,000, Abcam, ab290), mouse anti–α tubulin 
(DMA1) (1:10,000, Abcam, ab7291), rabbit anti–β-III tubulin (Abcam, 1:10,000, 18207), and anti-COX IV 
(20E8C12) (1:1,000, Abcam, ab14744). Following PBS washes, the following secondary antibodies were 
used: IR dye 800CW goat anti-mouse IgG (926-32210), IR dye 800CW goat anti-rabbit IgG (926-3211), IR 
dye 680RD goat anti-mouse IgG (926-68070), and IR dye 680RD goat anti-rabbit IgG (926-68071), all at 
1:5,000 and from LI-COR Biosciences. Membranes were imaged using an Odyssey Infrared Imaging Sys-
tem (Li-COR, Biosciences) and quantified using Image Studio software (Li-COR). Band intensities were 
then normalized to a loading to control to determine final relative protein expression.
Immunohistochemistry. Tissue from uninjected and gene therapy–treated mice was dissected and fixed 
in 4% paraformaldehyde in PBS for 4 hours at 4°C before being transferred into 30% sucrose solution over-
night at 4°C for cryoprotection. Tissue was embedded in OCT and using a cryostat, where heart (20 μm), 
liver (20 μm for GFP and UBA1 and 7 μm for Ly-76), and spinal cord (25 μm) sections were collected on 
polysine-coated slides (Thermo Scientific). Sections were permeabilized in 0.3% Triton X-100 in PBS and 
then blocking solution (4% BSA, 0.3% Triton X-100 in PBS) for 30 minutes at room temperature before 
overnight incubation with primary antibody solution at 4°C: rabbit anti-GFP (1:500, Abcam, ab290), 
mouse anti-UBA1 (1:200, Sigma-Aldrich, E3125), and rat anti-Ly76 (1:100, Abcam, ab91113). After PBS 
washes, sections were incubated with secondary antibody solution for 2 hours at room temperature: Alexa 
Fluor 488 donkey anti-rabbit IgG (1:500, Life Technologies, A-21206), Alexa Fluor 488 donkey anti-mouse 
IgG (1:500, Life Technologies, A-21202), and Alexa Fluor 488 goat anti-Rat IgG (1:200, Life Technolo-
gies A-11006). Sections were counterstained with Neurotrace 435/455 blue fluorescent Nissl stain (1:100, 
Life Technologies, N21479) or DAPI nuclei stain (1:1,000, Life Technologies, D1306) for 10 minutes. For 
GFP and UBA1 immunohistochemistry, images were taken using a Nikon A1R confocal system combined 
with a Ti:E inverted microscope (×40 objective). For Ly76 liver analysis, images were taken using a Nikon 
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eclipse e400 microscope (×10 objective) with a QICAM Fast 1394 camera and Improvision Velocity 4 
image capture software.
qRT-PCR. Extraction of  total RNA from hearts of  P7 uninjected and AAV9-UBA1–treated control 
mice (n = 3 mice for each treatment group) was achieved by using a RNAeasy Mini kit (Qiagen). Human 
blood cDNA was a gift from Kathy Evans, University of  Edinburgh. Samples were checked for DNA 
contamination and RNA concentration was determined by a Nanodrop 2000 spectrophotometer (Thermo 
Scientific). RNA integrity was checked by resolution of  two strong 28S and 18S rRNA bands in a ratio 
of  2:1 by agarose gel electrophoresis. cDNA was made from 1.5 μg RNA using a High Capacity cDNA 
Reverse Transcription kit (Life Technologies). Primers were designed that amplified transcripts unique to 
mouse Uba1 (forward CCTACATGACCAAGGAACTA, reverse AGCTGTTGAGTTCAGCAAGT), 
human UBA1 (forward TCTGTGCTCAGCATGGCCGG, reverse ATGAGGTCCTCGTCCAGGTTA), 
or a conserved sequence in both mouse Uba1 and human UBA1 (forward TGTCCAAGAAACGTCGCG, 
reverse CTCGTCTATGTCTGCTTCACTG). FL-SMN and Δ7 SMN primer sequences were taken from the 
published literature (51). qPCR reactions were performed with a Bio-Rad CFX Connect Optis module real-
time system thermocycler (Bio-Rad). For all primer pairs, cDNA was amplified in triplicate using KAPA 
SYBR FAST qPCR Master Mix (KAPA Biosystems) using a standard PCR program. Samples with Cq val-
ues >35 cycles were considered as having no detectable expression. A gene study using qPCR analysis was 
performed using Bio-Rad CFX manager 3.1 software where relative expression levels was normalized using 
the geometric mean of  3 housekeeping genes: PPIA (forward GCGTCTCCTTCGAGCTGTTTG, reverse 
TGAAAGTCACCACCCTGGCACAT), GAPDH, and OAZ1 (sequences previously described; see ref. 14).
Statistics. Data were collected and analyzed using Microsoft Excel and GraphPad Prism 6 software. 
Individual statistical tests are described in the main text and figure legends. For Student’s t tests, an 
unpaired, 2-tailed analysis was performed. For all analysis, P ≤ 0.05 was considered statistically significant. 
All data are expressed as mean ± SEM.
Study approval. All experimental procedures involving animals were conducted in accordance with 
United Kingdom Home Office regulations and were approved by a University of  Edinburgh internal ethics 
committee and veterinary staff.
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